Analysts Offer Predictions for Sanara MedTech Q2 Earnings

Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Stock analysts at HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for Sanara MedTech in a report released on Thursday, May 15th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.33) per share for the quarter, down from their previous estimate of ($0.29). HC Wainwright has a "Buy" rating and a $53.00 price objective on the stock. The consensus estimate for Sanara MedTech's current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech's Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.34) EPS.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). The firm had revenue of $23.43 million during the quarter, compared to analyst estimates of $23.48 million. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%.

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $46.00 price objective on shares of Sanara MedTech in a research note on Wednesday, March 26th.

Sanara MedTech Trading Down 1.9%

SMTI traded down $0.60 during mid-day trading on Monday, hitting $30.39. The stock had a trading volume of 27,384 shares, compared to its average volume of 26,132. The stock's fifty day simple moving average is $30.91 and its 200-day simple moving average is $33.36. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.23 and a quick ratio of 2.02. The firm has a market capitalization of $270.11 million, a price-to-earnings ratio of -30.70 and a beta of 1.38. Sanara MedTech has a 1-year low of $25.86 and a 1-year high of $39.08.

Institutional Investors Weigh In On Sanara MedTech

A number of hedge funds have recently modified their holdings of the business. Northern Trust Corp raised its position in shares of Sanara MedTech by 0.9% during the fourth quarter. Northern Trust Corp now owns 40,816 shares of the company's stock worth $1,355,000 after purchasing an additional 358 shares during the period. Rhumbline Advisers raised its holdings in Sanara MedTech by 14.9% during the 1st quarter. Rhumbline Advisers now owns 3,714 shares of the company's stock worth $115,000 after buying an additional 483 shares during the period. Wells Fargo & Company MN raised its holdings in Sanara MedTech by 53.9% during the 4th quarter. Wells Fargo & Company MN now owns 1,893 shares of the company's stock worth $63,000 after buying an additional 663 shares during the period. Barclays PLC raised its holdings in Sanara MedTech by 12.1% during the 4th quarter. Barclays PLC now owns 6,423 shares of the company's stock worth $213,000 after buying an additional 692 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Sanara MedTech by 6.3% during the 1st quarter. Bank of New York Mellon Corp now owns 13,880 shares of the company's stock worth $428,000 after buying an additional 826 shares during the period. Institutional investors and hedge funds own 8.10% of the company's stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.